Reports preliminary FY24 revenue $160M, consensus $180.61M. Preliminary unaudited cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2024 are expected to be approximately $229M. “We are excited by the significant sales momentum and robust revenue growth we continue to generate in our business, driven by expanding demand for our entire ZORYVE franchise,” said Frank Watanabe, president and chief executive officer of Arcutis. “We anticipate sustained ZORYVE sales growth throughout 2025 as our multiple product launches gain further traction and we secure new approvals, expand insurance coverage, and broaden access to primary care and pediatric practices through our commercial partnership with Kowa.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $20 from $19 at Mizuho
- American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls
- Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright
- Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings
- Arcutis Biotherapeutics submits sNDA for ZORYVE cream to FDA